格隆汇1月6日丨澳华内镜(688212.SH)公布，公司于近日收到公司股东顾康、顾小舟及其控制的小洲光 电出具的相关权益变动情况的告知函。2025年12月1日至2026年1月5日，顾小舟先生通过集中竞价交易 方式累计减持公司股份117.6300万股，通过大宗交易方式减持公司股份62.6700万股。顾康、顾小舟及其 控制的小洲光电合计持有公司股份数量由4,039.9660万股减少至3,859.6660万股，占公司总股本比例由 30.00%减少至28.66%，权益变动触及1%刻度。 ...

格隆汇1月6日丨澳华内镜(688212.SH)公布，公司于近日收到公司股东顾康、顾小舟及其控制的小洲光 电出具的相关权益变动情况的告知函。2025年12月1日至2026年1月5日，顾小舟先生通过集中竞价交易 方式累计减持公司股份117.6300万股，通过大宗交易方式减持公司股份62.6700万股。顾康、顾小舟及其 控制的小洲光电合计持有公司股份数量由4,039.9660万股减少至3,859.6660万股，占公司总股本比例由 30.00%减少至28.66%，权益变动触及1%刻度。 ...

澳华内镜1月5日大宗交易平台出现一笔成交，成交量62.67万股，成交金额2621.49万元，大宗交易成交 价为41.83元，相对今日收盘价折价8.01%。该笔交易的买方营业部为机构专用，卖方营业部为中信证券 股份有限公司上海浦东新区联洋证券营业部。 证券时报·数据宝统计显示，澳华内镜今日收盘价为45.47元，上涨4.03%，日换手率为1.71%，成交额为 1.04亿元，全天主力资金净流入275.31万元，近5日该股累计上涨1.54%，近5日资金合计净流入2600.63 万元。 1月5日澳华内镜大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | 62.67 | 2621.49 | 41.83 | -8.01 | 机构专 | 中信证券股份有限公司上海浦东新 | | | | | | 用 | 区联洋证券营业部 | （文章来源：证券时报网） 两融数据显示，该股最新融资余额为1.30亿元，近5日增加463.57万元， ...

1月5日，澳华内镜大宗交易成交62.67万股，成交额2621.49万元，占当日总成交额的20.16%，成交价 41.83元，较市场收盘价45.47元折价8.01%。 ...

（文章来源：证券时报网） 据Wind统计，截至2025年12月31日，沪深两市共有125只个股连续5日或5日以上获主力资金净买入。连 续获主力资金净买入天数最多的股票是天龙股份，已连续14个交易日获净买入；连续获主力资金净买入 天数较多的还有东方电气、华能水电、景旺电子、蕾奥规划、家家悦、美克家居、澳华内镜、常熟银行 等股。 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has experienced a decline in both revenue and net profit, indicating potential challenges in its financial performance [2] - As of December 24, Aohua Endoscopy's stock price decreased by 0.04%, with a trading volume of 58.05 million yuan and a net financing buy of -2.62 million yuan [1] - The company's financing balance reached 125 million yuan, accounting for 2.07% of its market capitalization, which is above the 80th percentile of the past year [1] Group 2 - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, a significant decline of 250.37% [2] - The number of shareholders increased by 41.52% to 5,549, while the average circulating shares per person decreased by 29.34% to 24,268 shares [2] - Aohua Endoscopy has distributed a total of 76.28 million yuan in dividends since its A-share listing, with 50.95 million yuan distributed in the last three years [3]

Core Viewpoint - Aohua Endoscopy experienced a decline of 3.21% in stock price on December 23, with a trading volume of 69.16 million yuan, indicating potential investor concerns regarding the company's financial performance and market position [1]. Financing and Trading Data - On December 23, Aohua Endoscopy had a financing buy-in amount of 8.64 million yuan, with a net financing buy of 5.35 million yuan after repayments [1]. - The total financing and securities balance reached 128 million yuan, accounting for 2.11% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - The company had no short selling activity on December 23, with a short selling balance of 28.72 thousand yuan, also above the 90th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, reflecting a significant decline of 250.37% [2]. - Cumulative cash dividends since the company's A-share listing amount to 76.28 million yuan, with 50.95 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 41.52% to 5,549, while the average circulating shares per person decreased by 29.34% to 24,268 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by the third-largest shareholder, with a 50.55 thousand share increase, while other funds reduced their holdings [3].

公司及全资子公司拟使用不超过人民币20,000万元（含本数）的部分闲置自有资金进行现金管理，在上 述额度内，资金可以滚动使用，使用期限自董事会审议通过之日起12个月内有效。 格隆汇12月23日丨澳华内镜(688212.SH)公布，公司拟使用不超过人民币6,000万元（含本数）的部分暂 时闲置募集资金进行现金管理，使用期限自董事会审议通过之日起12个月内有效。在不超过上述额度及 决议有效期内，资金可循环滚动使用。 ...